Patent 9403894 was granted and assigned to Zealand Pharma A/S on August, 2016 by the United States Patent and Trademark Office.
The invention provides materials and methods for promoting weight loss or preventing weight gain without affecting glycemic control. In particular, the invention provides novel glucagon analog peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the glucagon-like peptide-1 (GLP-1) receptor as compared to human glucagon.